Cellular immunotherapies have emerged as a successful therapeutic approach to fight a wide range of human diseases, including cancer. However, responses are limited to few patients and tumor types. An in-depth understanding of the complexity and dynamics of cellular immunotherapeutics, including what is behind their success and failure in a patient, the role of other immune cell types and molecular biomarkers in determining a response, is now paramount. As the cellular immunotherapy arsenal expands, whole-body non-invasive molecular imaging can shed a light on their in vivo fate and contribute to the reliable assessment of treatment outcome and prediction of therapeutic response. In this review, we outline the non-invasive strategies that can be tailored toward the molecular imaging of cellular immunotherapies and immune-related components, with a focus on those that have been extensively tested preclinically and are currently under clinical development or have already entered the clinical trial phase. We also provide a critical appraisal on the current role and consolidation of molecular imaging into clinical practice.
CITATION STYLE
Volpe, A., Adusumilli, P. S., Schöder, H., & Ponomarev, V. (2022, September 22). Imaging cellular immunotherapies and immune cell biomarkers: from preclinical studies to patients. Journal for ImmunoTherapy of Cancer. BMJ Publishing Group. https://doi.org/10.1136/jitc-2022-004902
Mendeley helps you to discover research relevant for your work.